Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 7, 2023 (4 years ago)

Finasteride Tablets USP 1 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: recalling drug products following an FDA inspection.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Finasteride Tablets USP 1 mg, 90-count bottle, Keeps, Rx Only, Manufactured for: Thirty Madison, Inc. New York, NY 10016 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA, NDC 71713-096-90 UPC 3 71713 09690 2

Affected NDC 71713-0096-90

Compare with the code on your package — it is the most precise check available.

Drug: Finasteride

Recalling firm
Accord Healthcare, Inc.
NDC code
71713-096-90
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0391-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Finasteride recalls

See all
Class II · Moderate risk

Finasteride Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-6976-3 D-0516-2023
Class II · Moderate risk

Finasteride

cGMP deviations

Terminated cGMP deviation Direct Rx NDC 61919-0733-90 D-0477-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-090-10 D-0392-2023
Class II · Moderate risk

Finasteride Tablets USP

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Accord Healthcare, Inc. NDC 16729-089-10 D-0390-2023

Other recalls by Accord Healthcare, Inc.

All 2023 recalls